Key result
Postoperative administration of levosimendan decreased the incidence of kidney failure at ICU discharge to 0% compared to 40% with beta-agonists in cardiac surgery patients with low cardiac output syndrome.
Why the study?
Levosimendan treats low cardiac output syndrome after cardiac surgery and seems to protect renal function, but its effects on postoperative kidney failure compared to beta-agonists needed assessment.
Does levosimendan reduce postoperative kidney failure in cardiac surgery patients with low cardiac output syndrome compared to beta-agonists?
Population
100 cardiac surgery patients with LCOS
Comparison
Levosimendan vs beta-agonists
Design
Quasi-experimental study
Authors
Loading...
May support levosimendan over beta-agonists to avert kidney failure in low-output cardiac surgery; leaves open need for RCT confirmation.
Observational (n=100)
No
Does levosimendan reduce postoperative kidney failure in cardiac surgery patients with low cardiac output syndrome compared to beta-agonists?
Absolute Event Rate: 0% vs 40%
p-value: p=<0.05
In cardiac surgery patients with low cardiac output syndrome, levosimendan administration was associated with a lower incidence of postoperative kidney failure compared to standard beta-agonist therapy.
Orriach et al. (2019) conducted an observational in Low cardiac output syndrome (LCOS) following heart surgery (n=100). Levosimendan vs. Beta-agonists (adrenaline or dobutamine) was evaluated on Incidence of kidney failure at ICU discharge among patients with renal dysfunction at LCOS diagnosis (p=<0.05). Postoperative administration of levosimendan decreased the incidence of kidney failure at ICU discharge to 0% compared to 40% with beta-agonists in cardiac surgery patients with low cardiac output syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: